反CD38单克隆抗体损害了CD34+的调动,并影响了多发性骨髓瘤患者的克隆性潜力
Arianna Zappaterra1,2,3, Ivan Civettini1,2, Anna Maria Cafro3
1Department of Medicine and Surgery, Milano-Bicocca University, Monza, Italy.
Blood transfusion = Trasfusione del sangue
|February 5, 2024
概括
对新诊断多发性骨髓瘤 (NDMM) 患者的达拉图穆马布基疗法显著影响CD34+细胞调动,往往需要更多的异位手术. 这种治疗也可能对BFU-E殖民地形成产生负面影响,不管细胞数量如何.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 干细胞移植 干细胞移植
背景情况:
- 自主干细胞移植是NDMM患者的标准.
- 基于达拉图穆马布的疗法越来越多地用于NDMM诱导.
- 有关达拉图穆马布对CD34+细胞调动的影响存在担忧.
研究的目的:
- 为了比较CD34+调动和克隆性潜力.
- 为了评估达拉图巴和非达拉图巴基疗法之间的结果.
- 为了评估NDMM患者在没有前期plerixafor给药的情况下产生的影响.
主要方法:
- 分析了41名NDMM患者的临床,动员和克隆基因数据.
- 在ASSTGrande Ospedale Metropolitano Niguarda进行的CD34+非瑞斯.
- 对BFU-E和CFU-GM的克隆性分析.
主要成果:
- 达拉图姆巴的患者需要更多的非 (75%vs24%) 和较低的CD34+计数 (38vs79/μL).
- 达拉图穆马布治疗患者中CD34+收获的中位数显著降低 (3.98比6.87×10^6/kg).
- 达拉图马布治疗与BFU-E殖民地形成负相关,独立于CD34+水平.
结论:
- 达拉图穆马布治疗对NDMM患者的CD34+调动产生影响.
- 在达拉图穆马布治疗的患者中观察到更高的异体要求.
- 达拉图穆马布可能会独立地损害BFU-E殖民地形成,需要采取缓解策略.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...